Actions
Pages
Subscribe for newsletter
Stories
Avail, a modular blockchain initiative that originated from Polygon, successfully raised $27 million in a seed funding round. The round was co-led by Peter Thiel's Founders Fund and Dragonfly, with additional investments from SevenX Ventures, Figment Capital, Nomad Capital, and some unidentified angel investors.
The funding will be directed towards the development of Avail's three core products: the data availability solution (DA), Nexus (a verification hub for unifying rollups), and Fusion (enhancing security through asset integration from other ecosystems), collectively known as the “Trinity.” These products are designed to support and enhance the functionality of blockchain networks by providing essential services such as data availability and security.
As blockchain adoption grows, scalability and interoperability challenges have hindered progress. Avail DA, the project's initial core component, is set to launch in early Q2 2024. It aims to offer space for data from "layer-2 networks" or "rollups," facilitating faster and more cost-effective transactions on base blockchains like Ethereum. This development highlights the growing interest in creating a more modular blockchain system architecture where transaction execution and data processing are handled separately.
"Avail's approach to modular blockchain architecture marks a significant leap forward in our quest for a scalable, secure, and interconnected blockchain ecosystem," says Anurag Arjun, co-founder of Avail.
Without disclosing specifics due to ongoing fundraising efforts, Avail's co-founder Anurag Arjun mentioned the company's valuation is in the several hundred million dollars range, based on a simple agreement for future tokens. Avail is also in the process of raising another funding round.
Avail began within Polygon in late 2020, supported by Polygon's treasury until March 2023. It has since become an independent entity and is gearing up for its mainnet launch with external funding.
The funding of Avail contributes to the over $99 billion capital invested in crypto startups across more than 4,900 funding rounds, demonstrating the growing financial support for the blockchain and cryptocurrency sector.
Story
Many corporations have pledged to combat biodiversity and nature loss, but face challenges in defining metrics and aligning actions with broader biodiversity goals.
As the global community grapples with escalating biodiversity loss and environmental degradation, innovative financial mechanisms like biodiversity funds represent a pathway for mobilizing capital towards sustainable practices. This initiative underscores the growing recognition of biodiversity as a paramount concern within the investment world.
European farmers have expressed concerns that the new environmental rules threaten their livelihoods, leading to protests across various EU countries. Farmers argue that the legislation imposes excessive restrictions, harms competition due to cheap imports, and results in low incomes.
The Lynx Global Biodiversity Fund represents a novel approach to aligning investment strategies with environmental sustainability goals. By prioritizing investments in companies actively engaged in preserving biodiversity, LAM is paving the way for a more sustainable future, demonstrating that financial success and ecological stewardship can go hand in hand.
Story
Sage Therapeutics and Biogen have introduced Zurzuvae, the first oral medication designed specifically for the treatment of postpartum depression (PPD).
With an estimated 500,000 new mothers in the U.S. alone facing PPD annually, the need for accessible, effective treatment options has never been more urgent. Zurzuvae's entry into the market is a testament to the evolving understanding and commitment to addressing maternal mental health with the seriousness it deserves.
Barry Greene, CEO of Sage Therapeutics, expressed optimism about Zurzuvae's market potential, stating, "It’s early but I do believe that Zurzuvae is the key to unlock the blockbuster potential of PPD, enabling us to help many women suffering from postpartum depression."
As Zurzuvae's market presence grows, its long-term impact on the treatment landscape for postpartum depression will be closely watched. The ongoing efforts by Sage and Biogen to ensure insurance coverage and to destigmatize PPD are crucial steps toward making Zurzuvae a staple in postnatal care. Furthermore, the companies' commitment to expanding treatment accessibility through a specialty pharmacy distribution network indicates a future where support for maternal mental health is both readily available and widely accepted.
Zurzuvae's mechanism, targeting the GABA-A receptors in the brain, offers a novel approach to PPD treatment, distinguishing it from traditional antidepressants. This scientific breakthrough provides a new lens through which to view and address the complexities of postpartum depression.
Story
Innovators
Scroll
Open
Close